Plasmablastic lymphoma through clonal expansion 17 years after EBV-positive DLBCL: case report and review Authors: Keita Ishii, Yasuhiro Arakawa, Kazuhito Suzuki, Masaharu Kawashima, Shingo Yano Published: 2026 ABSTRACT Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of B-cell lymphoma associated with immunodeficiency and Epstein–Barr virus (EBV) infection. Although PBL can develop from indolent lymphomas, its occurrence long after diffuse large B-cell lymphoma (DLBCL) is rare. A 67-year-old man was diagnosed with EBV-positive DLBCL 17 years ago and achieved a sustained remission following six cycles of R-CHOP therapy. Seventeen years after the initial DLBCL diagnosis, the patient developed PBL with EBV-positive tumor cells. After three cycles of EPOCH therapy, the patient achieved a partial response and underwent upfront autologous stem cell transplantation, resulting in complete remission. To investigate the clonal relationship between DLBCL and PBL, immunoglobulin gene repertoire analysis using next-generation sequencing was performed on both specimens. In the PBL specimen, immunoglobulin heavy chain rearrangement revealed a dominant clone with a complementarity-determining region 3 (CDR3) length of 38 amino acids. Although the DLBCL specimen lacked a dominant clone meeting the clonality criteria, a minor clone with a CDR3 sequence similar to that of the PBL dominant clone was detected. This clone exhibited an unusually long CDR3 sequence (37 amino acids), likely contained stop codons, and was considered a nonfunctional clone. These findings suggest that PBL originated through expansion of a pre-existing minor subclone that persisted since the initial DLBCL diagnosis, driven by long-term clonal dynamics. Our case highlights the potential utility of immunoglobulin repertoire analysis in identifying clonal relationships among lymphomas, supporting treatment decisions, and understanding the pathogenesis of secondary lymphomas. INTRODUCTION Plasmablastic lymphoma (PBL) is a rare subtype of B-cell non-Hodgkin lymphoma associated with a poor prognosis, with a median survival of 1.7 years.1 Its development is associated with immunodeficiency, including human immunodeficiency virus (HIV) infection, Epstein–Barr virus (EBV) infection, and organ transplantation. EBV infection has been observed in approximately 70% of PBL cases.2 Although PBL can arise from the histological transformation of indolent lymphomas such as chronic lymphocytic leukemia or follicular lymphoma,3,4 its occurrence in association with diffuse large B-cell lymphoma (DLBCL) has rarely been reported.5–7 When multiple lymphomas occur in the same patient, understanding their clonal relationship is crucial for accurate diagnosis and treatment. In a small proportion of cases, two distinct types of lymphomas occur synchronously or metachronously in the same patient. Analysis of rearranged antigen receptor genes is a useful approach to determine whether lymphomas are clonally related.8 Analysis of immunoglobulin (Ig) gene rearrangements using next-generation sequencing (NGS) is highly sensitive for detecting clonal rearrangements in B-cell lymphomas and enables accurate clonal comparisons.9,10 A study analyzing Ig gene rearrangement repertoires using NGS at the time of initial diagnosis and relapse in DLBCL found that 14% of patients showed different dominant clonotypes between primary and relapsed tumors, and this proportion increased to 37% among relapses occurring ≥4 years after diagnosis.11 These findings indicate that the interval between the initial diagnosis and relapse is a critical factor in determining clonal relationships, with longer intervals associated with a higher likelihood of clonally unrelated disease. EBV infection has been also implicated in the development of clonally unrelated lymphomas.11 Here, we report a case of EBV-positive PBL that developed 17 years after complete remission of EBV-positive DLBCL. Ig gene rearrangement analysis using NGS revealed that a minor clone, similar to the dominant PBL clone, was present in the EBV-positive DLBCL specimen. This case demonstrates that the PBL clone potentially arose from expansion of a pre-existing minor clone present at the time of the initial DLBCL diagnosis. MATERIALS AND METHODS Ig gene rearrangement repertoire analysis was performed as follows: Formalin-fixed paraffin-embedded (FFPE) sections were prepared from DLBCL and PBL tissue specimens. RNA was extracted from FFPE sections using an RNeasy FFPE Kit (Qiagen, Hilden, Germany), followed by DNase digestion. Total RNA was reverse transcribed into complementary DNA (cDNA) using reverse transcriptase with random primers. Ig gene amplification was performed using primer sets based on DeKosky et al.12 with library construction following established protocols.13,14 The primers target the Ig heavy chain variable (VH), diversity (D), and joining (JH) regions as well as the light chain variable (VL) and joining (JL) regions. The cDNA libraries were prepared using the GenNext NGS Library Prep Kit (TOYOBO, Osaka, Japan) and indexed using the IDT for Illumina TruSeq DNA UD Indexes V2. Libraries were sequenced with 75 nucleotides per pair (2 × 75 bp) paired-end reads on the NextSeq 1000 platform (Illumina, San Diego, CA, USA). After removing low-quality reads and adapter sequences, Ig sequences were analyzed using IgBLAST15 with the human reference database obtained from the international ImMunoGeneTics information system (IMGT). The sequence reads were aligned to the V, (D), and J genes and subsequently annotated to delineate the framework regions and complementarity-determining regions (CDRs). Statistical analyses were performed to evaluate the Ig repertoire. Clonal rearrangements were identified as previously described.10 CASE REPORT The patient’s clinical course is shown in Figure 1. A 67-year-old man was diagnosed with DLBCL, not otherwise specified (DLBCL, NOS) 17 years before the current presentation. He achieved complete remission after six courses of R-CHOP therapy (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone) and remained disease-free for 17 years. Clinical course of the present case. ASCT, autologous stem cell transplantation; CR, complete response; DA-EPOCH, dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin; DLBCL, diffuse large B-cell lymphoma; EBV-DNA, Epstein–Barr virus DNA; LDH, lactate dehydrogenase; MEAM, ranimustine, etoposide, cytarabine, and melphalan; PBL, plasmablastic lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; yrs, years. Seventeen years after the initial diagnosis of DLBCL, the patient developed right cervical lymphadenopathy. Fluorodeoxyglucose positron emission tomography/computed tomography (CT) revealed abnormal uptake in the pharynx, systemic lymph nodes, left adrenal gland, and left side of the sacrum. The patient was admitted for further evaluation and treatment because of fever, abdominal pain, anorexia, and acute kidney injury caused by a bulky abdominal mass. Laboratory tests demonstrated renal dysfunction with serum creatinine level of 4.24 mg/dL and markedly elevated levels of lactate dehydrogenase (3107 U/L) and soluble interleukin-2 receptor (3801 U/mL). CT revealed a bulky abdominal mass with bilateral hydronephrosis and generalized lymphadenopathy. Histopathological examination of a cervical lymph node biopsy revealed diffuse proliferation of large atypical lymphoid cells (Figure 2). The tumor cells exhibited enlarged nuclei, with irregular contours, some with multiple nucleoli and others with centrally prominent nucleoli, demonstrating a starry sky appearance. Atypical plasmacytoid lymphoid cells with a perinuclear halo were observed. Immunohistochemistry revealed that the tumor cells were negative for B cell markers (CD20, CD79a, and PAX5) and positive for CD138. The tumor cells were negative for Human Herpesvirus-8 and anaplastic lymphoma kinase, had an MIB-1 labeling index ≥ 95%, and were positive for EBV-encoded small RNA in-situ hybridization (EBER-ISH). Fluorescence in-situ hybridization analysis revealed MYC split signals, but no BCL2 rearrangements. Based on these findings, the patient was diagnosed with PBL. Bone marrow examination confirmed lymphomatous infiltration. Histopathological findings of PBL. (A, B) Hematoxylin and eosin staining reveals diffuse proliferation of large atypical lymphoid cells with multiple nucleoli or a centrally prominent nucleolus, exhibiting a starry-sky appearance. Immunohistochemical staining shows that the atypical cells are negative for CD20 (C) and PAX5 (D), and positive for CD138 (E). The CD20-positive cells in (C) represent residual normal B cells in the background. (F) In situ hybridization for Epstein–Barr virus-encoded small RNA is positive. Scale bars: 500 μm (A), 50 μm (B), 100 μm (C–F). After three cycles of dose-adjusted EPOCH therapy (etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin), the patient achieved a partial response. Given the cumulative cardiac toxicity of anthracyclines and the presence of high-risk features including a high International Prognostic Index and MYC gene rearrangement, upfront autologous stem cell transplantation (ASCT) was performed. Three months after the diagnosis of PBL, the patient underwent autologous peripheral blood SCT with MEAM conditioning (ranimustine, etoposide, cytarabine, and melphalan), resulting in complete remission. No relapse was observed 14 months after PBL diagnosis. Retrospective evaluation of the initial DLBCL specimen revealed diffuse proliferation of large atypical lymphoid cells with enlarged nuclei and irregular nuclear margins, which were positive for B-cell markers (CD20, CD79a, and PAX5) and EBER-ISH, and negative for CD138, leading to a diagnosis of EBV-positive DLBCL, NOS (Figure 3). To investigate the clonal relationship between the previous DLBCL and the subsequent PBL, Ig gene rearrangement repertoire analysis was performed. Serial section evaluations demonstrated that the initial DLBCL specimen contained 40% tumor cells, 20% inflammatory cells, and 40% necrotic cells, whereas the recurrent PBL specimen contained 80% tumor cells, 10% inflammatory cells, and 10% necrotic cells. Histopathological findings of DLBCL. (A, B) Hematoxylin and eosin staining reveals diffuse proliferation of large atypical lymphoid cells with enlarged nuclei and irregular nuclear margins. Immunohistochemical staining shows that atypical cells are positive for CD20 (C) and PAX5 (D), and negative for CD138 (E). (F) In situ hybridization for Epstein–Barr virus-encoded small RNA was positive. Scale bars: 500 μm (A), 50 μm (B), 100 μm (C–F). The results of Ig gene repertoire analysis of the PBL specimen (Figure 4A, Table 1A) were as follows: Ig heavy chain (IGH) rearrangement showed a dominant clone comprising 50.13% (IGHV4-4 / IGHD2-21 / IGHJ2) with a complementarity-determining region 3 (CDR3) length of 38 amino acids. Ig light chain (IGL) rearrangement revealed a dominant clone comprising 92.2% (IGLV3-16 / IGLJ3). These findings demonstrate the presence of clonal rearrangements in both heavy and light chains. Additionally, several low-frequency subclones harboring mutations in the CDR3 region of the dominant clone were identified. Immunoglobulin repertoire analysis comparing initial diagnosis and relapse samples. Bar graphs display the distribution of sequence reads by a complementarity determining region 3 (CDR3) amino acid length (x-axis) and clonotype abundance in percentages (y-axis). Tables below each graph summarize clones with CDR3 amino acid sequences similar to the dominant relapse clone. These related clones are highlighted in green in the corresponding graphs, with asterisks marking their positions. (A) Relapse PBL sample analysis revealed a dominant clone (50.13% of reads) with a CDR3 length of 38 amino acids, accompanied by several subclones containing mutations in the CDR3 region. (B) Initial diagnosis DLBCL sample analysis showed a more diverse clonal distribution without a clearly dominant clone. However, a clone with sequence similarity to the dominant relapse clone was identified (1.32% of reads, a CDR3 length of 37 amino acids). Table 1Immunoglobulin heavy chain V(D)J rearrangements and CDR3 sequences of the tumor clone(A) PBLRankV(D)J gene rearrangementCDR3 amino acid sequenceCDR3 amino acid lengthPercentage of Reads1V4-4D2-21J2GLNPPGGLRGPHPFTS*RFHALLNSLFKVLFNFPLRYL3850.1310V4-4D2-21J2GLNPPGGLRGPHPFTY*RFHALLNSLFKVLFNFPLRYL381.8011V4-4D2-21J3GLNPPGGLRGPHPFTS*RFHALL231.6313V4-4D2-21J2GLNPTGGLRGPHPFTS*RFHALLNSLFKVLFNFPLRYL381.5118V4-4D2-21J2GLNPQGGLRGPHPFTS*RFHALLNSLFKVLFNFPLRYL381.0219V4-4D2-21J6GLNPPGGLRGPHPFTS*RFHALLNSLFKVLFNFPLR361.0135V4-4D2-21J2GLNPPGGLRGPHPFTS*RFHALLNSLQSSFQLSLTVL370.4441V4-4D2-21J2GLNPPGGLRGPHPFTS*RFHALLNSLFKVLFNFPLRY370.3944V4-4D2-21J2GLXPPGGLRGPHPFTS*RFHALLNSLFKVLFNFPLRY370.3645V4-4D2-21J2GLNPPGGLRGPHPFTS*RFHALLNSLFKVLFNFPLRYL380.3546V4-4D1-7J2GLNPPGGLRGPHPFTS*RFHALWNSLFKVLFNFPLRY370.33(B) DLBCLRankV(D)J gene rearrangementCDR3 amino acid sequenceCDR3 amino acid lengthPercentage of Reads1V3-48D6-19J4VREGREVAGRGGQLDE168.352V4-34-J4ASGDC54.513V3-66-J4ASHDY54.134V4-4D3-10J5ASWGRIGV82.895V4-34D6-19J4AIAGGEQWLAIDY132.8245V4-4D2-21J2GLNPPGGLRGPHPFTS*RFHALLNSLFKVLFNFPLRY371.32 Immunoglobulin heavy chain V(D)J rearrangements and CDR3 sequences of the tumor clone The results of DLBCL specimen analysis (Figure 4B, Table 1B) were as follows: IGH rearrangement showed a dominant clone comprising 8.35% (IGHV3-48 / IGHD6-19 / IGHJ4) with a CDR3 length of 16 amino acids. The IGL rearrangement showed a dominant clone comprising 6.08% (IGLV1D / IGLJ2). Therefore, no clonal rearrangements were detected. However, the 45th most frequent IGH clone (IGHV4-4 / IGHD2-21 / IGHJ2) with a CDR3 length of 37 amino acids, accounting for 1.32%, was similar to the dominant IGH clone in the PBL specimen. In addition, this clone shared the same IGH rearrangement and CDR3 sequence as rank 41 in the PBL specimen. These findings suggest that, although the dominant clones of PBL and DLBCL were distinct, PBL may have arisen from expansion of a minor subclone (or a closely related clone) that was present at the time of DLBCL diagnosis. DISCUSSION PBL is a rare subtype of aggressive B-cell lymphoma that is typically associated with immunodeficiency.1 Reports on its metachronous occurrence following diffuse large B-cell lymphoma (DLBCL) and studies analyzing its Ig gene clonality remain limited.5–7 Repertoire analysis of Ig gene rearrangements using NGS in this case revealed that the PBL tumor clone was present at a low frequency in the initial DLBCL specimen. The findings from this case suggest possible aspects of PBL pathogenesis: PBL may emerge not only through the transformation of a previously dominant clone, but also through clonal expansion of a pre-existing minor clone. Notably, the minor clone identified in the initial DLBCL specimen had an unusually long CDR3 (37 amino acids), which likely contained stop codons, and represented a nonfunctional clone. The expansion of such a clone suggests that this clone was already neoplastic at the time of the initial DLBCL diagnosis, rather than representing a reactive B-cell population. Three cases have been reported in which both DLBCL and PBL occurred in the same patient (Table 2). One case involved the development of EBV-negative PBL during treatment for DLBCL, NOS with unknown EBV status.5 The remaining two cases involved the concurrent occurrence of PBL (EBV-positive in one case and unknown status in the other) and DLBCL, NOS with a few EBER-positive tumor cells.6,7 Clonality analyses by sequencing of the CDR3 region in the IGHV genes were conducted in the latter two cases and demonstrated that both lymphomas originated from the same B-cell clone.6,7 In contrast, our case is unique in that PBL developed metachronously after a prolonged interval following a complete response of EBV-positive DLBCL, with EBV appearing to be involved in the pathogenesis of both lymphomas. This difference may be related to the unique pattern of PBL pathogenesis associated with clonal expansion of a minor clone in our patient, as demonstrated by NGS analysis. Table 2Previous reports of lymphoma comprising DLBCL and PBLPrevious reportsAge (year)DLBCL subtypePBL occurrenceEBV statusTreatment of PBLSurvival after PBL diagnosisClonality analysisClonal relationshipMariniet al.555DLBCL, NOS (GC type)During DLBCL treatmentDLBCL: NAPBL: negativeESHAPDied for PBL3.5 monthsNot performedNAHashimotoet al.637DLBCL, NOS (non-GC type)At DLBCL diagnosisDLBCL: few EBER+ cellsPBL: NAR-CHOPDLBCL relapse4 yearsPCR-based IGHV–CDR3 sequencingRelatedImutaet al.784DLBCL, NOS (GC type)At DLBCL diagnosisDLBCL: few EBER+ cellsPBL: PositiveR-CHOPNo relapse11 monthsPCR-based IGHV–CDR3 sequencingRelatedOur case67EBV positive DLBCL, NOS17 years after DLBCL diagnosisDLBCL: positivePBL: positiveEPOCH and ASCTNo relapse14 monthsNGS-based Ig repertoire analysisPBL-related minor clone present at DLBCL diagnosisNote: In references 6 and 7, a rituximab-containing regimen was chosen to treat both DLBCL and PBL.ASCT, autologous stem cell transplantation; CDR3, complementarity-determining region; DLBCL, NOS, diffuse large B-cell lymphoma, not otherwise specified; EBER, Epstein–Barr virus-encoded small RNA; EBV, Epstein–Barr virus; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin; ESHAP, etoposide, methylprednisolone, cytarabine and cisplatin; GC, germinal center; Ig, immunoglobulin; IGHV, immunoglobulin heavy chain variable region; NA, not available; NGS, next-generation sequencing; PBL, plasmablastic lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Previous reports of lymphoma comprising DLBCL and PBL Note: In references 6 and 7, a rituximab-containing regimen was chosen to treat both DLBCL and PBL. ASCT, autologous stem cell transplantation; CDR3, complementarity-determining region; DLBCL, NOS, diffuse large B-cell lymphoma, not otherwise specified; EBER, Epstein–Barr virus-encoded small RNA; EBV, Epstein–Barr virus; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin; ESHAP, etoposide, methylprednisolone, cytarabine and cisplatin; GC, germinal center; Ig, immunoglobulin; IGHV, immunoglobulin heavy chain variable region; NA, not available; NGS, next-generation sequencing; PBL, plasmablastic lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Long-term intervals between the initial diagnosis and relapse are associated with clonally unrelated B-cell lymphomas. A study using next-generation sequencing (NGS) to compare the Ig gene repertoires of initial and relapsed DLBCL tumors demonstrated that the proportion of clonally unrelated relapse was 0% within two years, 20% at two to five years, and 27% after five years.11 In our case, a minor tumor clone with an extremely long CDR3 sequence (37 amino acids) present at the initial diagnosis expanded, followed by further alterations in the CDR3 region over 17 years, ultimately resulting in relapse as PBL. EBV infection has been reported as a factor contributing to the development of clonally unrelated lymphomas, and 43% of clonally unrelated relapses in DLBCL were EBV-positive, compared with only 5% in clonally related cases.11 This report also described a case of biclonal DLBCL in which a minor clone present at initial diagnosis became the dominant clone one year later and developed into a clonally unrelated lymphoma. In this case, both the primary and relapsed tumors were EBV-positive, suggesting that EBV infection may have contributed to the development of biclonality, regardless of the relapse interval. These observations suggest that, in cases with a long interval to relapse or in those with EBV involvement, the possibility of clonally unrelated relapse should be considered. Repertoire analysis of Ig gene rearrangements in relapsed lymphomas may not only support diagnosis, but also inform treatment decisions. Late relapses of DLBCL may represent genetically distinct diseases that have not been previously treated with chemotherapy, and repertoire analysis may inform optimal patient management.16 Although a repertoire analysis was not performed, retreatment with R-CHOP-like therapy has been reported to be an effective and reasonable option for patients with DLBCL with late relapse (>2 years).16 Therefore, repertoire analysis at the time of relapse may help determine the appropriate treatment intensity, especially in late relapse cases. Although the role of upfront ASCT in newly diagnosed PBL remains controversial,17 intensive therapy was considered appropriate in our case, given that PBL arose through the clonal expansion of a chemotherapy-resistant clone that persisted since the initial diagnosis. A limitation of our study is that a clearly dominant clone could not be identified in the DLBCL specimen. Although the tumor cell content (40%) exceeded the recommended threshold of >30%, high proportions of necrotic (40%) and inflammatory (20%) cells may have hindered accurate clone detection. Additionally, despite the sufficient RNA quality for library preparation, the 17-year storage period likely contributed to nucleic acid degradation, potentially causing false-negative results for clonal rearrangements corresponding to long amplicons.9,10,18 These same technical limitations may also explain the apparent difference in light chain repertoires between the DLBCL and PBL specimens (IGLV1D / IGLJ2 vs. IGLV3-16 / IGLJ3), particularly given the low frequency (6.08%) of the light chain clone and the sequence similarity between IGLJ2 and IGLJ3 segments. Notably, the identical IGH clone detected in both specimens (rank 45 in DLBCL and rank 41 in PBL) supports a direct clonal relationship despite this light chain discordance. In conclusion, this case demonstrates that PBL can arise through clonal expansion of a minor subclone that existed at the time of DLBCL diagnosis many years prior, highlighting the potential role of long-term clonal dynamics in lymphoma pathogenesis.